Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.
Triveni Bio has raised $65.0M in total funding. The most recent round was Series C. The last funding was announced in June 2026.
Triveni Bio's investors include Janus Henderson Investors, Goldman Sachs, Polaris Partners, OrbiMed, Cormorant Asset Management.
Triveni Bio is headquartered in Watertown, United States.
Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.
Triveni Bio is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Triveni Bio — Funding & Investors." VCBacked, June 17, 2026, https://www.vcbacked.co/company/triveni-bio. Accessed July 19, 2026.
VCBacked. (2026). Triveni Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/triveni-bio
{{cite web |title=Triveni Bio — Funding & Investors |url=https://www.vcbacked.co/company/triveni-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated